Announced Thu, 9 Jul · 20:05 IST
Board Approves Rights Issue up to Rs 50 Crores; Two Independent Directors Resign
Corporate Actions View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.2%1-day move
₹38.36
prior close
₹39.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9———-2.2-2.2-3.9-3.8-4.8-14.3————
Up moveDown movePending
AI summary
Bacil Pharma's board approved a Rights Issue of equity shares worth up to Rs 50 Crores, subject to shareholder and regulatory approvals. Authorised capital will rise by Rs 45 Crores to Rs 65 Crores total. Purva Sharegistry, Axis Bank, and Acuite Ratings were appointed as registrar, banker, and monitoring agency. Two Independent Directors resigned from the board. Issue terms like price and record date are yet to be decided.
Likely market impact
Rights Issue may dilute existing holdings unless shareholders participate fully. Two Independent Director resignations could raise governance concerns. Issue terms awaited.